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Background: In malaria endemic areas, continuous exposure to Plasmodium parasites leads to asymptomatic
carriers that provide a fundamental reservoir of parasites, contributing to the persistence of malaria transmission.
Therefore, in the present investigation, the presence and prevalence of malaria asymptomatic cases were
determined to evaluate the reservoir of infection in two malaria endemic areas with a previous history of malaria
transmission in the south of Iran, Bashagard and Ghale-Ganj districts of Hormozgan and Kerman provinces,
respectively, where malaria transmission has been drastically reduced in the recent years.
Methods: The population samples (n = 500 from each of the studied areas) were randomly collected from
non-febrile, long-term residing, aged two to over 60 years, during 2009–2010. Three identical surveys were carried
out in both study areas and in each phase all the consent participants were interviewed and clinically examined. In
all, three surveys to detect hidden parasite reservoirs (both Plasmodium falciparum and Plasmodium vivax), thick and
thin blood smears and a highly sensitive nested-PCR were applied. In addition, the sero-prevalence survey for
detecting malaria exposure was done by using a serological marker.
Results: In this study, P. vivax and P. falciparum parasites were not detected by light microscopy and nested-PCR
assay in all three surveys of samples. Antibody responses against P. vivax and P. falciparum were detected in 1 %
and 0.2 % of the total examined individuals, respectively, in Bashagard district. Regarding to Ghale-Ganj district,
about 0.9% of the individuals had IgG -specific antibody to P. vivax at the first and second surveys, but at the third
survey 0.45% of the participants had positive antibody to P. vivax parasite. IgG -specific antibody to P. falciparum
was detected in 0.2% of the participants at the first and follow-up surveys. The overall regional differences were not
statistically significant (P> 0.05).
Conclusion: Taken together, the lack of asymptomatic carrier with the evidence of extremely low sero-positive to
both P. vivax and P. falciparum among examined individuals supported the limited recent transmission in the
studied areas and, therefore, these parts of Iran have potential to eliminate the disease in the next few years.
However, continued follow up and action are still needed in both studied areas and also in their neighbouring
province, Sistan and Baluchistan, which has the highest reported cases of malaria in Iran and also, has the largest
border line with Afghanistan and Pakistan, with no elimination activities. This data will provide useful information for
managing elimination activities in Iran.* Correspondence: raeisia@tums.ac.ir; zakeris@yahoo.com
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Malaria remains an important cause of mortality and
morbidity in many parts of the world and it could have
adverse impact on the population, both from a health
and a socio-economic attitudes. In malaria endemic
areas, clinical manifestation of Plasmodium infection
varies from asymptomatic to severe and fatal malaria. In
high transmission areas, continuous exposures to Plas-
modium parasites lead to partial immunity and conse-
quently, create asymptomatic carriers in a given
population [1]. In addition, asymptomatic cases provide
a fundamental reservoir of parasites and they might be-
come gametocyte carriers, contributing in the persist-
ence of malaria transmission [2]. Therefore, the presence
of asymptomatic cases is a big challenge for the manage-
ment of the elimination programme in any malaria en-
demic area. In order to achieve a successful elimination,
detection of all parasite carriers by active case detection
and then treatment of all cases must be considered to
interrupt the malaria transmission in endemic areas.
Asymptomatic malaria infections were frequently
described in high and intermediate transmission areas in-
cluding Ghana [3,4], Kenya [2], Senegal [5,6], Gabon [7,8],
Nigeria [9,10], Uganda [11], Thailand [12], Burma [13] and
Yemen [14]. However, in recent years, such cases have also
been reported from low endemic areas such as Amazon
region of Brazil and Peru [15-23], Colombia [24], Solomon
Island [25] and Principe [26]. Notably, John and colleagues
[27] reported that administration of different malaria con-
trol interventions reduced the asymptomatic malaria cases
in an unstable malaria transmission area of Kenya and also
in high transmission endemic area of Sri Lanka [28]. Since
symptomless malaria consequences in the persistence of
the parasite reservoirs and increases malaria transmission
in human population, it can interfere with malaria elimin-
ation strategies. Therefore, to achieve successful elimin-
ation and finally eradication of malaria from the world,
survey on the presences and the prevalence of asymptom-
atic cases in diverse malaria settings is recommended.
In Iran, a country located in the south-west of Asia,
malaria was a major health problem with approximately
30-40% of the total mortality during 1921–1949 [29].
The National Malaria Eradication Programme was
initiated in 1957 and remarkable achievements were
obtained in most parts of the country. However, due to dif-
ferent obstructions in the south and south-east regions,
malaria transmission was maintained with more than 90%
of the total malaria cases in these areas. Therefore, in these
particular areas the eradication programme was re-
oriented to a control programme in 1980 [29]. Interest-
ingly, afterward, disease burden has significantly reduced
in the south and south-eastern parts of the country, due to
successful interventions in controlling malaria. Conse-
quently, since 2009, Iran, with 10 other countries enteredthe malaria pre-elimination programme with the technical
support from the World Health Organization [30,31].
Simultaneously, indoor residual spraying, long-lasting
impregnated bed nets (LLINs), active case detection and
case management with the first-line recommended ther-
apy for uncomplicated malaria, artemisinin combination
therapy (ACT), combined with improved diagnostic cap-
acities in all health facilities were all employed with a
greater rate in comparison with the malaria control
programme in Iran. In consequence, towards the reduc-
tion in transmission, based on the report by the Center
for Diseases Management and Control (CDMC), the
total malaria cases in Iran gradually dropped from
11,460 cases in 2008 to 6,122 in 2009 and as low as
3,031 cases in 2010 (Iranian CDMC, surveillance report,
unpublished).
It should be noted that prior to applying an elimin-
ation strategy, the targeting countries need to occupy
some constructions of active case detection for appropri-
ate treatment of the asymptomatic parasite carriers to
prevent major cause of sustained disease transmission.
Therefore, it is prerequisite to detect parasite carriers
that are undiagnosed by the light microscopy method or
persist in population after anti-malarial treatment caused
by drug resistance. To facilitate and complete the elimin-
ation efforts in Iran, this investigation was designed to
assess the presence of the parasite carriers free of clinical
symptoms in two malaria endemic districts with a history
of malaria transmission in the south of Iran, Bashagard
and Ghale-Ganj districts of Hormozgan and Kerman
provinces, where transmission has been drastically
reduced in recent years. The results of this study demon-
strate the effectiveness and feasibility of implementing
malaria elimination interventions in these malaria en-
demic areas of Iran.
Methods
Study area
This study was conducted in two malaria endemic areas
with a previous history of malaria transmission in the
south of Iran during 2009–2010. The transmission inten-
sity in both study areas may also vary depending on the
rainfall. The first study area was Bashagard district in the
south-eastern part of Hormozgan province (Figure 1A)
with a population of approximately 31,000 people.
Bashagard is a tropical, mountainous area with a low
level of population movement. The annual average
temperature of Bashagard is 26°C (7.7-44.2°C) and the
rainy season is from May to September with an annual
pluviometer index of 11.6 mm and relative humidity of
46.2%. According to the report of the CDMC in Iran, the
annual parasite incidence [API = (confirmed cases during
1 year/population under surveillance) x 1,000] in the


















Figure 1 Iran map showing the location of studied areas. A) Bashagard district from Hormozgan province, B) Ghale-Ganj district from Kerman
province in southern part of Iran. K = Kerman, H =Hormozgan, S & B= Sistan and Baluchistan.
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and transmission is year-round with two peaks, the first
in June-July and the second in September-October and
P. vivax parasite is the predominant species. The main
malaria vector is Anopheles stephensi, which accounts for
more than 90% of the anopheline fauna in Bashagard dis-
trict. Different malaria control measures have been used
in this region for the ultimate goal of the elimination
since 2009. Therefore, the total cases of malaria in
Bashagard district declined notably from 1,154 cases in
2008 to 197 and 11 cases in 2009 and 2010, respectively.
The second study area was Ghale-Ganj district in
Kerman province in the southern part of Iran with a
population of approximately 70,000 people (Figure 1B)
and an annual average temperature of 26°C. The API in
the studied area was 0.08 in 2009 (CDMC 2009, unpub-
lished data). In addition, malaria is seasonal and trans-
mission is year-round with two peaks, the first from
June-July and the second in October with P. vivax as the
predominant species in this area and the main malaria vec-
tor is An. stephensi. Since 2009, the malaria elimination
programme has been launched in this region; as a result,
the total cases in Ghale-Ganj declined from 198 cases in
2008 to 62 and 13 cases in 2009 and 2010, respectively. It
should be highlighted that comparable control measures
were implemented in the both studied areas.
Sample size calculation and sampling
This is the first study on detection of asymptomatic
cases in two southern endemic areas, thus there is no
available data for prevalence of asymptomatic cases
either from other endemic region in Iran or from itsneighbouring countries with comparable epidemiology.
Assuming 3% as the minimum prevalence of asymptom-
atic malaria, the required sample size was 776 to esti-
mate the prevalence with 0.9% (30% of the prevalence)
with 95% confidence coefficient. In order to take the
missing data into account, the sample size was increased
by 20%.
Samplings were carried out after repeated meetings and
discussions about the objectives of the project and its
protocols with communities in both study districts. The
population samples were collected from randomly long-
term residing individuals between the ages of two and
over 60 years from Bashagard (n = 500) and Ghale-Ganj
(n = 500) districts. The purpose of selecting different age
groups was to detect hidden parasites within the high
risk groups in different times of year (before, within and
after local malaria transmission peaks) and samples were
collected from August 2009 to March 2010 (Table 1)
over two weeks by the regional malaria supervisor of
each district.
Overall, three identical surveys were carried out in
both study areas to check the variation of the preva-
lence in different malaria transmission peaks. In each
phase all the consent participants were interviewed and
clinically examined. In addition, for each individual’s
demographic data with the episode of malaria in the
past 10 years, anti-malarial treatment, and travels to the
highly malaria endemic areas in neighbouring countries,
Afghanistan and Pakistan, were recorded by question-
naire. Besides, exclusion criteria in this investigation
were: non-consenting individuals during the follow-up
study, symptomless individuals who preferred to be




No. of collected samples Median age No. of collected samples Median age
August 2009 (after the first peak) 500 20 500 18
October 2009 (within the second peak) 474 20 453 18
March 2010 (after the second peak) 456 19 442 18
*Malaria transmission in Bashagard district in Hormozgan province is year-round with two peaks, the first in June-July and the second in September-October.
**Malaria transmission in Ghale-Ganj district in Kerman province is year-round with two peaks, the first from June-July and the second in October.
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tory of fever within the past 48 hours (≥ 37.5°C), having
other malaria symptoms, patients who had received
anti-malarial therapy in the past four weeks prior to the
sampling and also during follow-up, pregnant women
as well as children under two years old. During the sec-
ond and third cross sectional surveys in both studied
areas, some of the consent participants were lost due to
death, absence in the area during the sampling period,
pregnancy, travel to highly malaria endemic areas of Af-
ghanistan and Pakistan, refusing to give blood and so
on (Table 1).
Regarding the follow-up protocol for detection of
asymptomatic carriers, in case of any microscopy and/or
nested PCR positive individual (who remained symptom-
less for 60 days, regardless of the onset of the infection),
they were invited to go through the 60-day follow-up
under the constant supervision of the local healthcares.
They also were clinically examined and asked about mal-
aria symptoms and at the same time blood smear was
collected. All individuals who presented symptoms dur-
ing the follow-up period were immediately treated and
recorded as symptomatic patients, then excluded from
the study.
In all three surveys and also the follow-up study to de-
tect Plasmodium infection, firstly, thick and thin blood
smears were prepared from all of the participants
monthly by a well-trained microscopist in the local mal-
aria health centres and were also cross-checked in Mal-
aria and Vector Research Group (MVRG), Institut
Pasteur, Iran. The initial slides were considered negative
if no parasites were observed after examining 200 fields
of Giemsa-stained thick blood smears or counting 1000
red blood cells (RBCs) in a Giemsa stained thin blood
film at X1,000 magnification under immersion oil. Sec-
ondly, 2 ml venous blood was collected in tubes contain-
ing EDTA for detection of sub-patent Plasmodium
species by nested-PCR [32] and sero-positive individuals
by serological marker.
In this work, informed consent was obtained before
blood collection from adults or parents or legal guar-
dians of children who were a participant in this study.
This study was approved by the Ethical Review Commit-
tee of Research in Institut Pasteur, Iran.Assessment of plasmodium vivax and plasmodium
falciparum prevalence by nested-PCR
DNA was extracted from 300 μL blood samples by using
the commercially available DNA purification kit (Pro-
mega, Madison, WI, USA), and kept at −20°C until use.
DNA of P. vivax and P. falciparum was detected by
nested-PCR amplification of the small sub-unit riboso-
mal ribonucleic acid (18ssrRNA) genes. The nest-1 PCR
was performed similarly for both Pasmodium species
using primers and cycling parameters described previ-
ously [32]. In addition, to detect P. vivax DNA, nest-2
PCR amplification was done by using newly designed
forward primer (5’-AGGACTTTCTTTGCTTCGGC-3’)
and reverse primer (5’-AAGGCACTGAAGGAAGCA
ATC-3’) in the MVRG lab to amplify a 419 bp fragment.
Amplification was carried out in a final volume of 25 μL
including 1 μL nest-1 PCR product as a template,
250 nM of primers, 10 mM Tris–HCl (pH 8.3), 50 mM
KCl, 2 mM MgCl2, 125 μM of each of the four deoxynu-
cleotide triphosphates and 0.4 U of Taq polymerase
(Invitrogen, Carlsbad, CA). The cycling condition for
nest-2 PCR of P. vivax corresponding gene was as fol-
lows: 95°C for 5 min, 25 cycles of 94°C for 1 min, 58°C
for 1 min, 72°C for 1 min followed by 72°C for 15 min.
The nest-2 PCR amplification of P. falciparum was car-
ried out as described previously [32]. Two negative con-
trols were included in each set of amplification reactions,
one with no DNA and the other was genomic DNA pre-
pared from healthy individuals with no history of malaria,
living in non-malaria endemic regions. In addition,
extracted DNA from continuous culture of P. falciparum
(K1 strain) and microscopically positive P. vivax were
used as positive controls for the amplification of P. falcip-
arum and P. vivax 18ssrRNA gene, respectively. All the
products were visualized in 2% agarose gels containing
ethidium bromide under ultraviolet transillumination.
Production of recombinant PvMSP-119 and PfMSP-119 as
antigens
In this study, the 19-kDa C-terminal region of mero-
zoite surface protein 1 of P. vivax and P. falciparum
(PvMSP-119 and PfMSP-119), one of the highly im-
munogenic antigen during the natural Plasmodium in-
fection in human [33,34], was expressed and used as
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[35,36]. Briefly, the PvMSP-119 (GenBank accession no.
AY925098) was expressed as a recombinant protein
fused to the C-terminal of poly-histidine (6-His) tag in
Escherichia coli M15 and purified using Ni-NTA agar-
ose (Qiagen, Germany) [35]. In addition, four pre-
determined PfMSP-119 variants in local P. falciparum
isolates (E/TSR/L, E/TSG/L, E/KNG/F and Q/KNG/L
with GenBank accession nos. HM569746, HM569747,
HM569748 and HM569750 respectively) [36] were
expressed as recombinant proteins fused to the
C-terminus of glutathione S-transferase (GST) of Schis-
tosoma japonicum using the pGEX-KG vector in
Escherichia coli BL21 and purified by using glutathione
sepharose 4B resin (Amersham Biosciences, USA) [36].
The fractions containing PfMSP-119 were desalted with
Econo-Pac 10DG columns (BioRad, USA) according to
the manufacturer’s manual and analysed by SDS-PAGE
on 12% gels. Afterward, immuno-blotting was per-
formed to confirm the specificity of the expressed
PvMSP-119 with anti-His antibody (Qiagen, Germany,
only for rPvMSP-119) as well as positive P. vivax
infected human sera and in case of rPfMSP-119 only
sera from positive infected human sera with this para-
site were used.
Detection of anti-PvMSP-119 and -PfMSP-119 specific
antibodies using ELISA
Collected plasma samples from individuals of both study
areas were used for the presence of the anti-PvMSP-119-
and -PfMSP-119-specific IgG, IgG1 and IgG3 antibodies
by indirect ELISAs as described previously with some
minor modifications [35,36]. Briefly, Maxisorp flat-
bottom, 96-well microplates (Grainer, LaborTechnic,
Germany) were coated with 35 and 200 ng (50 ng of the
each PfMSP-119variant) of purified PvMSP-119 and
PfMSP-119 antigens, respectively, in 0.06 M carbonate-
bicarbonate buffer (pH 9.6) and incubated at 4°C over-
night. After washing three times with PBS containing
0.05% Tween 20 (PBS-T), the microplates were blocked
with 100 μl PBS containing 2% BSA and 0.05% Tween 20
(pH 7.4) at room temperature for 1 h. In the next step,
the sera samples were added to each well at 1:500 and
1:200 dilutions for PvMSP-119 and PfMSP-119 antigens,
respectively. The plates were washed and incubated with
100 μl of anti-human IgG horseradish peroxidase (diluted
1:25,000 in PBS-T, Sigma, USA) for 1 h at RT. Then,
plates were washed and the enzyme reaction was devel-
oped with an enzyme-specific substrate, o-phenylenedi-
amine dihydrochloride-H2O2 (OPD, Sigma, USA). The
reaction was stopped by 2 N sulfuric acid and the absorb-
ance was measured at 490 nm. To detect IgG1 and IgG3
subclasses, an ELISA was performed as described above
except for the secondary antibodies that biotin-conjugated isotype-specific mouse anti-human IgGs
(Sigma, USA) were used at dilution of 1:3,000 and after
the washing step, streptavidin-peroxidase conjugate
(Sigma, USA) was added at dilution of 1:2,500. The
ELISA cut-offs were calculated from the mean of negative
sera (n = 30) of the healthy individuals non-exposed to
malaria transmission plus three standard deviation (SD)
for both recombinant antigens and the ODs more than
cut-off values were considered as positive. In each plate,
sera with patent P. vivax or P. falciparum infection were
used as positive control.Avidity assay
Functional affinity of IgG-PvMSP-119 or -PfMSP-119
antibodies was determined in positive sera using avidity
ELISA as described by Hedman and co-workers, with
minor modifications [37]. Avidity index (AI) was calcu-
lated as the ratio of the OD of urea-treated wells to the
OD value of untreated samples multiplied by 100. An AI
less than 30% was considered low-avidity, between 30%
and 50% as intermediate avidity and greater than 50% as
high-avidity antibodies [37].Statistical analysis
The differences between the proportion of positive IgG
responders in Bashagard and Ghale-Ganj districts were
analysed using the Chi-square (X2) test. In addition,
Wilcoxon signed rank test was used for comparison be-
tween the levels of the IgG antibody through various
sampling stages. SPSS 16.0 for windows software (SPSS
Inc. USA) was used for all statistical analysis. P <0.05
was considered significant.Results
Demographic data
At the beginning of the first survey in both study dis-
tricts a total of, 1,000 consent individuals (500 from each
study area) accepted to participate in this study. How-
ever, in the two other surveys, during follow-up sam-
pling, 456 (91.2%) individuals (median age, 19) from
Bashagard and 442 (88.4%) individuals (median age, 18)
from Ghale-Ganj districts had been recruitment and
completed the second and third surveys (Table 1). In the
present investigation, the distribution of the different age
groups has been shown in Table 2, and the majority of
the individuals were six to 15 years old in both districts.
About, 41% of the total individuals enrolled from both
study areas had at least one microscopy-positive blood
film in the past 10 years and the majority of them had a
history of infection with P. vivax parasite. This informa-
tion was obtained based on filled questionnaires by con-
sent participants and confirmed by the local healthcare
recording documents.
Table 2 The distribution of age group among participants
Bashagard Ghale-Ganj
Age group (y) No. of samples (%) No. of samples (%)
≤5 10 (2) 11 (2.2)
6-15 160 (32) 196 (39.2)
16-20 96(19.2) 78 (15.6)
21-40 147 (29.4) 158 (31.6)
>40 87 (17.4) 57 (11.4)
Total 500 (100) 500 (100)
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nested-PCR methods
At the all-longitudinal active case detection in the three
surveys in Bashagard and Ghale-Ganj districts, none of
the examined blood subset collected through all three
phases of follow-up were positive for P. vivax and/or P.
falciparum parasites by using light microscopy and
nested-PCR assays.
Sero-prevalence of anti- MSP-119 antibodies
The presence of anti-PvMSP-119 and -PfMSP-119 IgG
were evaluated by ELISA using recombinant PvMSP-119
and PfMSP-119 as antigens. The level of OD490nm and
epidemiological data of the positive sera from Bashagard
district at different phases of the study have been shown
in Table 3A and 3B. In this area, 1% of the total exam-
ined individuals had positive IgG PvMSP-119-specific
antibody at the first, second and third phases of sampling
in August (after the first local peak), October (within the
second peak) 2009 and March (after the second peak)
2010 (Table 3A)(P> 0.05). The mean level of IgG
PvMSP-119-specific antibody significantly decreased
from 0.82 ± 0.33 at the first survey to 0.64 ± 0.1 in theTable 3 The antibody level (OD490nm) of anti-PvMSP-119 (A) -P
positive individuals in three surveys in Bashagard district, Ho
A)
Survey 1
Code Age (y) sex IgG IgG1 IgG3
1 12 M 0.61 0.52 -
2 15 F 0.77 0.42 -
3 18 M 1.40 1.04 -
4 21 F 0.55 0.40 -
5 28 F 0.77 0.40 -
B)
Survey 1
Code Age (y) sex IgG IgG1 IgG3
1 35 M 0.81 0.57 -
*OD: Optical Density. The cut-off values were considered 0.44, 0.19 and 0.18 for IgG
**OD: Optical Density. The cut-off values were considered 0.52, 0.16 and 0.18 for IgGsecond survey and finally to the 0.59 ± 0.1 in the last
survey (P< 0.05, Wilcoxon signed rank test). Further-
more, 0.2% of the individuals in Bashagard district had
IgG PfMSP-119-specific antibody in the first survey
(after the first peak) that was persistent in follow-up
studies (Table 3B). All IgG PvMSP-119- or PfMSP-119-
specific antibodies in positive sera had also positive
IgG1 but not IgG3 subclasses antibodies to both recom-
binant antigens (Table 3).
Regarding to Ghale-Ganj district, 0.9% of the indivi-
duals had IgG PvMSP-119-specific antibody at the first
and second surveys (Table 4A). Besides, at the third sur-
vey 0.45% of participants had positive IgG response to
PvMSP-119 antigen (Table 4A). The mean level of IgG
PvMSP-119-specific antibody decreased from 0.68 ± 0.08
at the first to 0.59 ± 0.08 in the second survey and finally
to 0.52 ± 0.1 in the third survey (P> 0.05, Wilcoxon
signed rank test). Regarding to IgG PfMSP-119-specific
antibody response, 0.2% of the participants showed posi-
tive antibody response at the first and follow-up surveys
(Table 4B). Analysis of the subclasses antibodies showed
IgG1 and IgG3 PvMSP-119- or PfMSP-119-specific anti-
bodies in positive follow-up samples of Ghale-Ganj dis-
trict (Table 4). In addition, comparison of the positive
IgG responders in Bashagard and Ghale-Ganj districts
did not show any significant difference (P> 0.05).
Additionally, the avidity index (AI) was measured for
IgG-PvMSP-119 and -PfMSP-119 antibodies in positive
sera. The results showed that in Bashagard district, the
positive sera to PvMSP-119 had low (60%) or intermedi-
ate (40%) IgG antibodies in the collected samples; how-
ever, the only positive serum to PfMSP-119 antigen
showed high avidity IgG antibody (Table 5). Concerning
Ghale-Ganj district, 3 of 4 (75%) IgG positive sera for
PvMSP-119 had low and/or intermediate IgG antibodiesfMSP-119 (B) IgG, IgG1 and IgG3 antibodies of sero-
rmozgan, Iran
Mean OD490*
survey 2 Survey 3
IgG IgG1 IgG3 IgG IgG1 IgG3
0.55 0.51 - 0.48 0.20 -
0.76 0.41 - 0.73 0.41 -
0.72 0.44 - 0.6 0.35 -
0.52 0.35 - 0.48 0.30 -
0.68 0.37 - 0.65 0.32 -
Mean OD490**
Survey 2 Survey 3
IgG IgG1 IgG3 IgG IgG1 IgG3
0.73 0.46 - 0.57 0.31 -
, IgG1 and IgG3, respectively.
, IgG1 and IgG3, respectively.
Table 4 The antibody level (OD490nm) of anti-PvMSP-119 (A) -PfMSP-119 (B) IgG, IgG1 and IgG3 antibodies in
sero-positive individuals in three surveys in Ghale-Ganj district, Kerman province, Iran
A) Mean OD490*
Survey 1 survey 2 Survey 3
Code Age(y) sex IgG IgG1 IgG3 IgG IgG1 IgG3 IgG IgG1 IgG3
1 17 F 0.58 0.57 - 0.49 0.3 - 0.43 0.19 -
2 17 M 0.65 0.79 - 0.57 0.61 - 0.55 0.58 -
3 18 M 0.78 0.8 - 0.61 0.42 - 0.45 0.2 -
4 60 M 0.72 0.47 0.95 0.69 0.41 0.86 0.67 0.4 0.8
B) Mean OD490**
Survey 1 Survey 2 Survey 3
Code Age (y) sex IgG IgG1 IgG3 IgG IgG1 IgG3 IgG IgG1 IgG3
1 25 F 0.6 0.45 - 0.59 0.4 - 0.55 0.35 -
*The cut-off values were considered 0.46, 0.2 and 0.18 for IgG, IgG1 and IgG3, respectively.
**The cut-off values were considered 0.5, 0.14 and 0.16 for IgG, IgG1 and IgG3, respectively.
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ples had high avidity IgG antibody. Regarding PfMSP-119
antigen, the only positive sample had intermediate IgG
antibodies (Table 5).Discussion
The prevalence and incidence of malaria has been redu-
cing as the result of passive and active case detection
and also scaling up malaria surveillance and control
interventions in Iran since 2008. In the present study,
therefore, to achieve and maintain the malaria elimin-
ation campaign in Iran, the presence and prevalence of
malaria asymptomatic cases as healthy carriers of para-
sites were determined to evaluate the reservoir of infec-
tions in two malaria endemic areas (Hormozgan and
Kerman provinces) for the first time, by using light mi-
croscopy and nested-PCR methods.Table 5 The distribution of anti-PvMSP-119 and -PfMSP-119 Ig
Antigen Code Age Age










PfMSP-119 1 25 21
Low avidity IgG antibodies, Avidity Index (AI) <30%.
Intermediate avidity IgG antibodies, Avidity Index (AI) between 30 - 50%.
High avidity IgG antibodies, Avidity Index (AI) >50%.According to the updated surveillance report in 2010
by the Iranian CDMC (unpublished), the total cases in
Bashagard districts were 11 P. vivax mono-infection
confirmed by microscopy method and all of them were
indigenous. However, from Ghale-Ganj districts, 13
microscopically confirmed malaria cases were reported
and of the 13 cases nine were indigenous while the rest of
the cases were imported from Pakistan (n =1) and
Afghanistan (n= 3). Notably, only one indigenous malaria
case from each study area was under four years old. In-
deed, in concordance with Iranian CDMC’s report, the
present results confirmed and recommended that malaria
incidence dramatically reduced throughout applying
massive malaria control tools in these regions in recent
years. Therefore, the absence of asymptomatic carries and
the low incidence of malaria cases in the studied areas
confirm that the achievement of malaria elimination can
be easily obtained in the near future in both districts.G antibodies avidity by age group in analysed individuals
Avidity Index (AI)
group (y) sex Survey 1 Survey 2 Survey 3
6-14 M 26.75 29.54 29.43
15-20 F 21.1 22.37 23.6
15-20 M 33.57 33.67 49.83
21-40 F 54.68 42.01 44.46
21-40 F 20.3 19.57 20.5
21-40 F 55.84 57.58 59.77
15-20 F 35.64 36.27 21.59
15-20 M 49.81 49 48.81
15-20 M 24.83 24 23.5
>40 M 77.14 75 74.7
-40 years F 47.3 46.2 46
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parasitaemia missed by microscopy represent a major
challenge for a malaria surveillance system and it sug-
gests the remaining potential for malaria transmission in
a given populations. Therefore, to detect very low para-
sitaemia in the population under study, a highly sensitive
nested-PCR method was used as it is a robust diagnostic
tool to identify simultaneously P. falciparum and P.
vivax parasite infections in epidemiological studies [38].
Remarkably, in this study, no hidden Plasmodium para-
sites were detected during all the three surveys. As a re-
sult, hidden parasite reservoirs are not a big challenge
for the elimination campaign in these regions; however
achieving the final phase of elimination and entering the
eradication phase (malaria free) in these regions, active
case detection of symptomatic and asymptomatic carries
with the purpose of proper treatment should be continu-
ously carried out. This data is also in agreement with the
reported results from Sri Lanka [28] and Kenya [27] that
confirmed reducing asymptomatic malaria in parallel to
decreasing symptomatic malaria because of applying dif-
ferent malaria control interventions firmly. In contrast,
the present results were against the reported findings
from different malaria endemic regions in the world
where the malaria endemicity is still considered as low
transmission areas [16,19,23,24].
Consistent with the data from the Iranian CDMC
(based on collected data from various health centres
throughout the malaria endemic areas in the country)
and using serological tools in this study, the results
revealed that P. vivax was the most prevalent species in
both study areas. Since this is the first sero-prevalence
work using recombinant MSP-119 in Iran, thus there is
no possibility for direct comparison to previous studies.
However, the explanation for the detection of a very low
prevalence of anti-MSP-119 among examined subjects in
both studied areas might be explained by the extensive
use of LLINs with other malaria interventions since 2008
that support the decline in the disease burden and thus,
the absence of any re-infection.
Different studies reported that serological markers
such as blood stage proteins of Plasmodium species (e.g.
MSP-119 and/or AMA-1) can be useful and reliable tools
for evaluating the malaria transmission intensity, moni-
toring changes in malaria transmission as well as malaria
control and elimination activities [39-41]. Indeed, the
prevalence of the anti-MSP-119 with an expected half-life
of 1–50 years [42] revealed the longer periods of exposure
to malaria infection over many years and thus is correlated
to the malaria transmission intensity. In the current inves-
tigation among all 1000 examined individuals there were
no detectable Plasmodium species but an exposure of
about <2% to antibodies against the merozoite stage of the
parasites was recognized. As the overall sero-prevalence ofanti-PvMSP-119 and PfMSP-119 was extremely low with
no detectable asymptomatic infection by nested-PCR in
the examined individuals and there were no clinical signs
of malaria infections during the follow-up study, hence in
the absence of the re-infection, anti-MSP-119 antibodies
could be sustained in the previous exposure to the para-
sites many years earlier. This result was also supported by
the age of all sero-positive individuals that was above
10 years. Also, the reduction of antibody level during the
follow-up surveys was in accordance to previous studies
showing that antibodies rising to PvMSP-119 and
PfMSP-119 are short half-life in Brazil and Iran [33,36].
Furthermore, as shown by previous studies, high affinity/
avidity antibodies are expected to play an important role
in the effective humoral immune response and it has
been associated with more repeated infections with in-
creasing age [43,44]. In this investigation, with the ab-
sence of any evidence for re-infection, the avidity results
did not change in any of the examined subjects during
the follow-up period which might have required further
avidity maturation.
Moreover, with the lack of hidden parasites from both
study districts with the previous history of malaria
transmission, the future surveillance and assessments of
the hidden parasites should focus on areas with
reported malaria cases in the past six-12 months in
these provinces. Also, as a critical part of malaria elim-
ination is detecting the prevalence and the presence of
hidden parasites in malaria endemic areas, thus, similar
study is highly needed in the neighbouring province,
Sistan and Baluchistan, with the highest reported cases
of malaria in Iran. This province is located in the
south-eastern part of Iran with the largest border line
with Afghanistan and Pakistan as well as with both
studied districts. Providing comparable data from Sistan
and Baluchistan province with high rates of imported
malaria cased from two highly endemic malaria coun-
tries, Afghanistan and Pakistan, with no elimination ac-
tivities will reduce the chance of local epidemic and re-
establishment of disease transmission.
Conclusion
Taken together, the lack of asymptomatic carrier, a sub-
stantial decline in malaria cases and also tremendously
low sero-positive of anti- PvMSP-119 and PfMSP-119
antibodies supported that the recent malaria elimination
activities dropped the level of malaria in both studied
districts. In addition, the results showed that these two
studied districts in the south of Iran could successfully
move from the pre-elimination phase toward eliminating
the disease and it is achievable in the next few years.
However, to avoid any problem during elimination activ-
ities in Iran, surveillance of symptomatic and asymptom-
atic malaria cases combined with other interventions
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plementation of malaria elimination in Iran. Therefore,
to provide baseline data on the malaria situation in Iran
toward designing malaria elimination and eradication
strategies based on the local epidemiology, such survey
could be extended to other areas at risk in particular,
Sistan and Baluchistan province with the highest
reported malaria cases in Iran.
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